AKT1 and Hepatic fibrosis: While RBO-treated groups (0.2 and 0.4 mL/rat) two-week post-liver fibrosis induction showed marked dose-related deceased immuno-expression of p-Akt and PDGF-BB, particularly in the high dose treated group compared to the high dose TAA group and silymarin treated group.